Priavoid GmbH

Privately held: no public share price · Germany

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Amyloid-beta-42 oligomerizationSmall molecule
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026Topline resultPRI-002Phase 2 PRImus-AD topline: CDR-SB efficacy endpoint not met; safety endpoint met

Financial reports

No financial reports recorded.